In a patient with a history of alcohol abuse who has elevated total bilirubin, normal transaminases (AST and ALT), and elevated ammonia, what is the most likely diagnosis and recommended management?

Elevated Total Bilirubin, Normal AST/ALT, and Elevated Ammonia in Alcohol Abuse

This clinical presentation most likely represents severe alcoholic hepatitis (AH) with hepatic encephalopathy, and the patient requires immediate assessment for disease severity using prognostic scoring systems (Maddrey DF, MELD) to determine candidacy for corticosteroid therapy. 1

Diagnostic Considerations

The combination of elevated bilirubin with normal or minimally elevated transaminases in the context of alcohol abuse is characteristic of:

• Alcoholic hepatitis with cholestatic features - The elevated ammonia indicates hepatic synthetic dysfunction and likely hepatic encephalopathy, suggesting severe disease 1
• AST/ALT ratio typically >1.5-2.0 in AH - While your patient has normal transaminases, this can occur in severe cholestatic AH where bilirubin elevation predominates 1
• Isolated hyperbilirubinemia can rarely occur in alcohol-related liver disease without significant transaminase elevation, though this is uncommon 2

Key Diagnostic Criteria for Alcoholic Hepatitis

The diagnosis requires 1:

• Heavy drinking (>40-60 g/day) for >6 months with <60 days abstinence before jaundice onset
• Serum bilirubin >3.0 mg/dL
• Serum AST >50 IU/L but <400 IU/L (though your case shows normal levels)
• AST/ALT ratio >1.5
• Elevated ammonia suggests hepatic encephalopathy complicating the presentation 1

Important caveat: Normal ammonia essentially rules out hepatic encephalopathy as the cause of altered mental status if present, and should prompt evaluation for other causes of delirium 1. However, elevated ammonia with liver disease strongly supports HE diagnosis.

Immediate Assessment Required

Severity Stratification

Calculate prognostic scores immediately 1:

• Maddrey Discriminant Function (mDF): mDF = 4.6 × (PT patient - PT control) + serum bilirubin (mg/dL)

  • mDF ≥32 defines severe AH requiring treatment consideration
  • Without treatment, 1-month mortality approaches 40-50% 1

• MELD Score: MELD >20 predicts high 90-day mortality 1

• Glasgow Alcoholic Hepatitis Score (GAHS): Score ≥9 indicates poor prognosis 1

Rule Out Competing Diagnoses

Before confirming AH, exclude 1, 3:

• Extrahepatic biliary obstruction - Obtain ultrasound abdomen to exclude biliary dilation 1
• Viral hepatitis - Check hepatitis B surface antigen, hepatitis C antibody
• Drug-induced liver injury - Review medications, especially acetaminophen
• Autoimmune hepatitis - Check ANA, ASMA, IgG levels
• Ischemic hepatitis - Assess for hypotensive episodes
• Wilson disease (if age <40) - Check ceruloplasmin, 24-hour urinary copper

Consider Liver Biopsy

Liver biopsy should be strongly considered in this case given the atypical presentation (normal transaminases) and if severe disease requiring corticosteroids is suspected 1:

• Confirms diagnosis (10-20% of clinically suspected AH have alternative diagnoses) 1
• Provides prognostic information (severe inflammation predicts steroid responsiveness) 1
• Transjugular approach preferred if coagulopathy or ascites present 1

Management Algorithm

General Supportive Measures (All Patients)

Regardless of severity 1:

1. Alcohol abstinence - Cornerstone of therapy; arrange addiction medicine consultation 1, 4
2. Thiamine supplementation - Prevent Wernicke's encephalopathy with B-complex vitamins 1
3. Hepatic encephalopathy treatment - Lactulose and rifaximin for elevated ammonia 1
4. Nutritional support - Target 35-40 kcal/kg/day and 1.2-1.5 g/kg protein daily 1
   • Consider enteral feeding tube if unable to maintain adequate oral intake 1
5. Infection surveillance - Screen systematically before and during treatment; infections dramatically worsen prognosis 1
6. Avoid nephrotoxic agents - Stop diuretics, NSAIDs; avoid beta-blockers (increase AKI risk) 1

Specific Treatment for Severe Disease (mDF ≥32 or MELD >20)

If no active infection present 1:

• Prednisolone 40 mg/day OR methylprednisolone 32 mg/day for 28 days 1

  • Provides short-term mortality benefit in approximately 50-60% of patients 1, 5
  • Does NOT improve medium to long-term survival 1

• Consider adding N-acetylcysteine (intravenous for 5 days) to corticosteroids 1

• Assess response at Day 7 using Lille score 1:

  • Early non-responders (Lille score >0.45) should have corticosteroids stopped 1
  • Non-responders should be evaluated for early liver transplantation if highly selected candidates 1

Infection Prophylaxis Considerations

Given immunosuppression from corticosteroids 1:

• Aggressive screening for invasive aspergillosis in ICU patients or MELD ≥24 (16% incidence, very high mortality) 1
• Consider prophylactic antibiotics in high-risk patients, though this remains investigational 1
• Monitor for pneumocystis pneumonia (8% incidence in severe AH on steroids) 1

Critical Pitfalls to Avoid

1. Do not assume normal transaminases exclude severe AH - Cholestatic variant can present this way 2
2. Do not start corticosteroids without ruling out infection - Systematic infection screening is mandatory 1
3. Do not continue corticosteroids beyond Day 7 in non-responders - Increases infection risk without benefit 1
4. Do not overlook alcohol use disorder treatment - Long-term survival depends on abstinence 1, 4
5. Do not delay transplant evaluation in steroid non-responders - Early LT referral improves outcomes in selected patients 1

Follow-Up and Long-Term Management

• Multidisciplinary care model involving hepatology, addiction medicine, psychiatry, and social work 4
• Pharmacotherapy for alcohol use disorder - Consider naltrexone, acamprosate, or disulfiram 4
• Monitor for hepatocellular carcinoma if cirrhosis present (ultrasound every 6 months) 1
• Liver transplantation evaluation for advanced cirrhosis or steroid-refractory severe AH 1, 5